Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-Month Delayed-Release Risedronate Formulations Compared to 150 mg Once-a-Month Immediate-Release Risedronate for 3 Months in Postmenopausal Women Age 45-80

Trial Profile

Study Assessing the Efficacy, Safety, and Pharmacokinetics of 75 and 100 mg Once-a-Month Delayed-Release Risedronate Formulations Compared to 150 mg Once-a-Month Immediate-Release Risedronate for 3 Months in Postmenopausal Women Age 45-80

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2015

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 07 Jun 2010 'Warner Chilcott' added as trial affiliate and sponsor as reported by ClinicalTrials.gov record.
    • 07 Jun 2010 Patient numbers amended from 205 to 204 as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top